Hyunki Kim1, Karri Folks1, Lingling Guo2, James George2, Jeffrey Sellers3, Donald Buchsbaum4, Kurt Zinn1
1Radiology, University of Alabama at Birmingham, Birmingham, AL, USA; 2Surgery, University of Alabama at Birmingham, Birmingham, AL, USA; 3Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL, USA; 4Radiation Oncology, University of Alabama at Birmingham, Birmingham, AL, USA
DCE MR imaging was applied for pancreatic tumor xenografts implanted in SCID mice orthotopically, detecting a significant therapeutic response in 3 days after anti-EGFR antibody and irinotecan administration. The early Ktrans decrease responsive to therapy was well correlated with tumor-growth suppression and bioluminescence-signal decrease over the 6 days of treatment. Therefore, DCE-MRI may be a reasonable approach to determine individualized tumor response against anti-EGFR antibody and/or irinotecan in clinical trials.